4.6 Article

Cannabidiol Enhances Cabozantinib-Induced Apoptotic Cell Death via Phosphorylation of p53 Regulated by ER Stress in Hepatocellular Carcinoma

Journal

CANCERS
Volume 15, Issue 15, Pages -

Publisher

MDPI
DOI: 10.3390/cancers15153987

Keywords

cannabidiol; cabozantinib; apoptosis; p53; endoplasmic reticulum stress

Categories

Ask authors/readers for more resources

This study provides evidence that the combination treatment of cabozantinib and CBD leads to increased apoptosis in HCC cells. This enhanced apoptosis is mediated, at least in part, through the induction of ER stress and subsequent activation of the p53 pathway. However, there is no association found between the combination treatment and CNR.
Simple Summary This study provides evidence that cabozantinib and CBD combination treatment leads to increased apoptosis in HCC cells. We propose that this enhanced apoptosis is mediated, at least in part, through the induction of ER stress and subsequent activation of the p53 pathway. However, our study did not find any association between the combination treatment and CNR. Cannabidiol (CBD), a primary constituent in hemp and cannabis, exerts broad pharmacological effects against various diseases, including cancer. Additionally, cabozantinib, a potent multi-kinase inhibitor, has been approved for treating patients with advanced hepatocellular carcinoma (HCC). Recently, there has been an increase in research on combination therapy using cabozantinib to improve efficacy and safety when treating patients. Here, we investigated the effect of a combination treatment of cabozantinib and CBD on HCC cells. CBD treatment enhanced the sensitivity of HCC cells to cabozantinib-mediated anti-cancer activity by increasing cytotoxicity and apoptosis. Phospho-kinase array analysis demonstrated that the apoptotic effect of the combination treatment was mainly related to p53 phosphorylation regulated by endoplasmic reticulum (ER) stress when compared to other kinases. The inhibition of p53 expression and ER stress suppressed the apoptotic effect of the combination treatment, revealing no changes in the expression of Bax, Bcl-2, cleaved caspase-3, cleaved caspase-8, or cleaved caspase-9. Notably, the effect of the combination treatment was not associated with cannabinoid receptor 1 (CNR1) and the CNR2 signaling pathways. Our findings suggest that the combination therapy of cabozantinib and CBD provides therapeutic efficacy against HCC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available